Home / Stocks / Natco Pharma Ltd.
NATCOPHARM

Natco Pharma Ltd. Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹821.95

Change

+1.35 (0.16%)

Open

₹818.5

Prev. Close

₹820.6

Day High

₹827.95

Day Low

₹802.2

Volume Analysis

Traded

735,748

Delivered

372,538

Delivery %

50.63%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (24.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (1)

  • •Strong 3-year EPS growth (26.4%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹858.29 ₹843.12 ₹832.54 ₹817.37 ₹806.79 ₹791.62 ₹781.04
Fibonacci ₹843.12 ₹833.28 ₹827.21 ₹817.37 ₹807.53 ₹801.46 ₹791.62
Camarilla ₹829.03 ₹826.67 ₹824.31 ₹817.37 ₹819.59 ₹817.23 ₹814.87

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-7.46%

1 Week

+1.63%

1 Month

+4.78%

3 Months

-6.85%

6 Months

-29.73%

1 Year

-5.45%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹977.77

Current price is at or below the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

11.37%

Net margin 26.84% × asset turnover 0.35x × equity multiplier 1.21x

Company Overview

Sector

Healthcare

Market Cap

₹15,881 Cr

P/E (TTM)

19.1

ROE

17.1%

Book Value

₹541.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Natco Pharma Ltd. holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 70/100. The strongest factor is Financial Strength (100/100), while Momentum (8/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (24.0%); promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

70/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

86

Valuation

70

Cash Flow

75

Corporate Governance

53

Momentum

8

Institutional Ownership

50

Business Quality

86

Risk & Volatility

51

Liquidity

90

From Screener.in

  • +Company has delivered good profit growth of 28.1% CAGR over last 5 years
  • −Promoter holding has decreased over last quarter: -3.19%
  • −Tax rate seems low
  • −Earnings include an other income of Rs.247 Cr.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

NATCO filed Q2 FY27 earnings call transcript; revenue ₹1,019.4 crore, PAT ₹202.6 crore, FY27 PAT guided ₹775–800 crore.

Newspaper publication for Unaudited Financail Results for the Qaurter and Half year ended September 30, 2026 and Record date for the 2nd Interim Dividend for …

Audio link shared for Q2 FY27 earnings conference call held on 13 November 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 1,031 759 1,068 1,363 1,371 475 1,221 1,329 1,363 647 739 735 967
Expenses + 573 490 571 558 567 436 673 758 784 489 612 549 709
Operating Profit 458 268 497 805 804 39 548 571 579 159 128 186 258
OPM % 44.0% 35.0% 47.0% 59.0% 59.0% 8.0% 45.0% 43.0% 42.0% 25.0% 17.0% 25.0% 27.0%
Other Income + 29 37 42 48 64 176 66 62 100 58 78 59 52
Interest 4 5 6 5 4 4 10 3 13 10 11 13 18
Depreciation 44 44 56 44 46 47 98 58 52 46 50 47 49
Profit before tax 440 256 478 804 818 164 506 572 614 161 144 186 243
Tax % 16.0% 17.0% 19.0% 17.0% 17.0% 19.0% 20.0% 16.0% 16.0% 13.0% -62.0% 34.0% 29.0%
Net Profit + 369 213 386 668 676 132 406 480 518 151 269 206 203
EPS in Rs 20 12 21 37 38 7 23 27 29 8 15 11 11
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 139 54 19 19 33 -37 14 -2 -1 36 -39 -45 -29

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 825 1,042 2,020 2,185 2,094 1,915 2,052 1,945 2,707 3,999 4,430 4,078 3,089
Expenses + 615 777 1,337 1,256 1,300 1,332 1,446 1,681 1,772 2,245 2,234 2,617 2,358
Operating Profit 210 266 683 928 795 583 606 264 936 1,754 2,196 1,462 731
OPM % 25.0% 25.0% 34.0% 42.0% 38.0% 30.0% 30.0% 14.0% 35.0% 44.0% 50.0% 36.0% 24.0%
Other Income + 0 12 14 40 130 107 104 99 105 126 354 272 247
Interest 32 23 18 15 19 22 13 18 14 19 24 37 51
Depreciation 47 51 54 66 81 100 117 143 164 187 235 207 193
Profit before tax 132 204 624 887 825 569 580 202 862 1,674 2,291 1,491 734
Tax % 1.0% 24.0% 22.0% 22.0% 22.0% 19.0% 24.0% 16.0% 17.0% 17.0% 18.0% 8.0% —
Net Profit + 130 156 485 695 642 458 442 170 715 1,388 1,883 1,418 829
EPS in Rs 8 9 28 37 35 25 24 9 39 77 104 79 46
Dividend Payout % 12.0% 14.0% 24.0% 22.0% 18.0% 27.0% 22.0% 48.0% 14.0% 12.0% 6.0% 6.0% —
Sales growth 12 26 94 8 -4 -9 7 -5 39 48 11 -8 -30

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 813 1,261 1,614 3,035 3,452 3,737 4,085 4,227 4,837 5,817 7,571 9,185 9,729
Borrowings + 312 113 222 173 386 316 268 416 167 371 279 714 1,033
Other Liabilities + 226 413 446 470 428 498 403 430 617 682 744 1,138 1,001
Total Liabilities 1,384 1,822 2,318 3,715 4,303 4,588 4,792 5,109 5,657 6,906 8,631 11,074 11,799
Fixed Assets + 710 710 833 1,019 1,227 1,584 2,023 2,312 2,427 2,491 2,698 2,803 2,846
CWIP 129 212 336 480 638 518 223 130 64 137 225 294 396
Investments 2 22 32 76 169 112 304 308 392 539 474 3,127 4,417
Other Assets + 543 878 1,116 2,140 2,270 2,373 2,242 2,360 2,774 3,739 5,234 4,850 4,140
Total Assets 1,384 1,822 2,318 3,715 4,303 4,588 4,792 5,109 5,657 6,906 8,631 11,074 11,799
Equity Capital 33 35 35 37 36 36 36 36 36 36 36 36 36

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 93 112 346 464 669 417 299 46 849 1,212 1,697 1,768
Cash from Investing Activity + -120 -176 -299 -1,116 -611 -175 -107 4 -465 -1,026 -1,436 -1,987
Cash from Financing Activity + 29 154 -48 651 -51 -251 -186 35 -363 -247 -211 298
Net Cash Flow 2 90 -1 -2 7 -8 6 85 21 -62 50 79
Free Cash Flow -25 -44 66 57 225 81 92 -142 674 855 1,300 1,379
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 55 60 69 72 107 90 71 36 110 85 94 148

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 49.71% → 46.22%
  Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026 Oct 2026
Public 24.46% 24.99% 26.13% 26.88% 27.3% 29.12% 30.56% 29.97% 27.74% 27.97% 28.46% 27.59%
Promoters 49.71% 49.71% 49.62% 49.62% 49.56% 49.56% 49.48% 49.48% 49.41% 49.41% 49.39% 46.22%
FII 16.14% 17.45% 17.51% 17.94% 17.49% 15.52% 14.09% 15.16% 17.37% 16.99% 15.99% 15.37%
DII 9.69% 7.86% 6.75% 5.59% 5.64% 5.81% 5.87% 5.39% 5.46% 5.63% 6.16% 10.82%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Natco Pharma Ltd. (this stock) 15,881 19.1 1.5 17.1%
Indegene Limited 15,640 36.7 4.67 14.4%
Jubilant Pharmova Ltd 14,883 50.4 2.08 6.53%
Poly Medicure Limited 17,041 53.9 5.22 9.8%
Molbio Diagnostics Ltd 17,111 236.0 11.89 15.6%
Vijaya Diagnostic Cen Ltd 14,524 71.3 13.69 18.9%
Dr Agarwals Health Care L 17,460 97.5 7.8 6.41%

Which Mutual Funds Hold Natco Pharma Ltd.?

Frequently Asked Questions about Natco Pharma Ltd.

Community Sentiment

What are other investors saying about Natco Pharma Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.